MedTrace Logo

Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

NCT07784959 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-08-25

No results posted yet for this study

Summary

This is a multi-center, open label, Phase 1b study of NXP900 in combination with lorlatinib in subjects with advanced, ALK-positive non-small cell lung cancer (NSCLC)

Conditions

  • ALK Positive
  • ALK Positive Non-small Cell Lung Cancer
  • NSCLC
  • ALK+ Non-Small-Cell Lung Carcinoma

Interventions

DRUG

NXP900

NXP900 is an orally administered inhibitor of SRC family kinases (SFK)

DRUG

Lorlatinib

Lorlatinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC)

Sponsors & Collaborators

  • Nuvectis Pharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Christine Lovly, MD, PhD · City of Hope Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-17
Primary Completion
2027-08-31
Completion
2028-02-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07784959 on ClinicalTrials.gov